

Evolut Clinical Guideline 3106 for Myeloid Growth Factors (MGF)

Guideline Number: Evolut_CG_3106	<u>Applicable Codes</u>	
<i>"Evolut" refers to Evolut Health LLC and Evolut Specialty Services, Inc.</i> <i>© 2011 - 2025 Evolut. All rights Reserved.</i>		
Original Date: February 2011	Last Revised Date: May 2025	Implementation Date: May 2025

TABLE OF CONTENTS

STATEMENT	3
PURPOSE	3
INDICATIONS	3
MGF IN MEMBERS RECEIVING CONCURRENT CHEMORADIATION	3
MYELODYSPLASTIC SYNDROMES (MDS)	3
PERIPHERAL BLOOD STEM CELL (PBSC) MOBILIZATION	4
PROPHYLAXIS/PREVENTION OF FEBRILE NEUTROPENIA FROM CHEMOTHERAPY	4
TREATMENT OF FEBRILE NEUTROPENIA	4
CONTRAINDICATIONS/WARNINGS	4
EXCLUSION CRITERIA	5
CODING AND STANDARDS	6
CODES	6
APPLICABLE LINES OF BUSINESS	7
POLICY HISTORY	7
LEGAL AND COMPLIANCE	7
GUIDELINE APPROVAL	8
Committee	8
DISCLAIMER	8
REFERENCES	9
ATTACHMENT A: LOW RISK REGIMENS (LESS THAN 10% FN RISK)	11
ATTACHMENT B: INTERMEDIATE RISK REGIMENS (10% TO 20% FN RISK)	28
ATTACHMENT C: HIGH RISK REGIMENS (GREATER THAN 20% FN RISK)	32
ATTACHMENT D: MGF INDICATIONS FOR FEBRILE NEUTROPENIA PRIMARY AND SECONDARY PROPHYLAXIS	

Primary Prophylaxis of FN	Secondary Prophylaxis of FN
<u>Definition</u> Use of a G-CSF to prevent febrile neutropenia* in a patient receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.	<u>Definition</u> - Per NCCN Guidelines for Management of Neutropenia (growthfactors.pdf nccn.org): - Secondary prophylaxis with G-CSFs is recommended after a febrile neutropenic <u>or</u> dose-limiting neutropenic event* during prior chemotherapy cycle. - Per ASCO Guidelines (Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update ascopubs.org): - Secondary prophylaxis with a CSF is recommended for patients who experienced a neutropenic complication from a prior cycle of chemotherapy (for which primary prophylaxis was not received), in which a reduced dose or treatment delay may compromise disease-free or overall survival or treatment outcome. In many clinical situations, dose reduction or delay may be a reasonable alternative.
<u>Additional Definitions</u> Febrile Neutropenia: defined as single temp $\geq 38^{\circ}\text{C}$ and <500 neutrophils/μL (ANC 0.5) or $<1,000$ neutrophils/μL (ANC 1.0) and a predicted decline to <500 over the next 48 hours. Dose-Limiting Neutropenic Event: - Per NCCN: <i>could be a nadir count or day of treatment count that could otherwise impact planned dose of chemotherapy</i> - Per AACR: <i>criteria for defining dose-limiting criteria (hematology):</i> - Grade 3 neutropenia for >7 consecutive days - Grade 3 thrombocytopenia for >7 consecutive days - Grade 4 thrombocytopenia Febrile neutropenia (ANC, including bands, $<1.0 \times 10^9/\text{L}$, fever $\geq 38.5^{\circ}\text{C}$)	

STATEMENT

Purpose

To define and describe the accepted indications for Myeloid Growth Factors (MGFs): Neupogen (filgrastim), Granix (tbo-filgrastim), Sargramostim (leukine), Zarxio (filgrastim-sndz), Nivestym (filgrastim-aafi), Releuko (filgrastim-ayow), Nypozi (filgrastim-txid), Neulasta/Neulasta Onpro Kit (pegfilgrastim), Fulphila (pegfilgrastim-jmdb), Udenyca (pegfilgrastim-cbqv), Ziextenzo (pegfilgrastim-bmez), Nyvepria (pegfilgrastim-apgf), Fylnetra (pegfilgrastim-pbbk), Stimufend (pegfilgrastim-fpgk), Rolvedon (eflapeggrastim), and Ryzneuta (efbemalenoggrastim alfa-vuxw) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

Evolent is responsible for processing all medication requests from network ordering providers. Medications not authorized by Evolent may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

INDICATIONS

Continuation requests for a not-approvable medication shall be exempt from this Evolent policy provided

- The member has not experienced disease progression on the requested medication AND
- The requested medication was used within the last year without a lapse of more than 30 days of having an active authorization AND
- Additional medication(s) are not being added to the continuation request.

MGF in Members Receiving Concurrent Chemoradiation

- For members on concurrent chemoradiation, the use of short-acting MGFs (e.g., filgrastim/filgrastim biosimilar/sargramostim) may be used on a case-by-case basis. If approved, it is recommended that concurrent radiation be held during MGF administration.

Myelodysplastic Syndromes (MDS)

- A short acting MGF (e.g., filgrastim/filgrastim biosimilar) is being used in combination with lenalidomide and/or epoetin or darbepoetin alpha in members with no response to erythropoietin alone OR
- The member has MDS and a short acting MGF (e.g., filgrastim/filgrastim biosimilar) is being used for neutropenia AND prevention of infections.

Peripheral Blood Stem Cell (PBSC) Mobilization

- A short acting MGF (e.g., filgrastim/filgrastim biosimilar/sargramostim) may be used for PBSC mobilization prior to and during leukapheresis in members undergoing an autologous PBSC collection and therapy.

Prophylaxis/Prevention of Febrile Neutropenia from Chemotherapy

- The member has a solid tumor or non-myeloid malignancy and MGF will be used as primary prophylaxis for febrile neutropenia from chemotherapy in any of the following clinical settings:
 - MGF is being used for chemotherapy with high-risk (greater than 20%) for febrile neutropenia (please refer to Attachment C for a list of drugs/regimens with high-risk for febrile neutropenia) OR
 - MGF is being used with chemotherapy with an intermediate risk (10% to 20%) for febrile neutropenia AND the member has ONE or more of the following risk factors:
 - Age greater than or equal to 65 years; extensive prior chemotherapy or radiation therapy; persistent/pre-existing neutropenia; bone marrow involvement by tumor; recent surgery and/or open wounds; liver dysfunction (Bili greater than 2.0), or renal dysfunction (CrCl less than 50).
- OR
- MGF may be used as secondary prophylaxis for members with solid tumors or non-myeloid malignancies who experienced any of the following:
 - A prior episode of febrile neutropenia with the current chemotherapy OR
 - A neutropenic event leading to chemotherapy dose delay or dose decrease in the curative intent setting.

Treatment of Febrile Neutropenia

- Member has documented febrile neutropenia as defined by the Infectious Disease Society of America as: An ANC (Absolute Neutrophil Count) of less than 1,000 cells/microL AND a single temperature of greater than or equal to 38.3 degree C (101 degree F) or a temperature of greater than or equal to 38.0 degree C (100.4 degree F) sustained over a 1 hour period AND
- A short-acting MGF (e.g., filgrastim/filgrastim biosimilar/sargramostim) is being used with appropriate antibiotic therapy.

CONTRAINDICATIONS/WARNINGS

- Contraindications
 - Filgrastim, pegfilgrastim, efbemalenograftim alfa-vuxw, and eflapegrastim
 - History of serious allergic reactions to granulocyte-stimulating factors such as efbemalenograftim alfa-vuxw, eflapegrastim, pegfilgrastim, or filgrastim

products, or any component of the formulation.

- Sargramostim
 - History of serious allergic reactions, including anaphylaxis, to human granulocyte-macrophage colony stimulating factor such as sargramostim, yeast-derived products, or any component of the formulation.

EXCLUSION CRITERIA

- Use of MGF with Low FN Risk regimens. An exception will be made in the following clinical settings:
 - If a member experienced dose reduction AND cycle delay with curative intent chemotherapy OR
 - A member had a prior episode of febrile neutropenia on the same regimen.
- Use of long acting MGF [e.g., pegfilgrastim/pegfilgrastim biosimilars/Rolvedon (eflapregastim)/ Ryzneuta (efbemalenogastim alfa-vuxw)] in members on concurrent chemoradiation.
- Use for prevention of febrile neutropenia when CDK4/6 inhibitors are being used.
- Primary prophylaxis for febrile neutropenia with MGF is not recommended for use with non-cytotoxic drugs, please refer to attachment A for a list of low risk for FN drugs/regimens. MGF use with these drugs will be reviewed on a case-by-case basis (e.g., when clinically indicated, in combination with chemotherapy, or as secondary prophylaxis).
- Use of MGF for the treatment of afebrile neutropenia.
- The member is not receiving myelosuppressive chemotherapy for non-myeloid malignancy or solid tumor.
- Use of Pegfilgrastim/Eflapregastim/Efbemalenogastim alfa-vuxw with weekly myelosuppressive chemotherapy regimens (Neupogen, Leukine, Zarxio, Nivestym, Releuko, Granix, or Nypozi should be used in these circumstances).
- Neupogen (filgrastim), Granix (tbo-filgrastim), Sargramostim (leukine), Zarxio (filgrastim-sndz), Nivestym (filgrastim-aafi), Releuko (filgrastim-ayow), or Nypozi (filgrastim-txid) use within 7 days of Pegfilgrastim/Eflapregastim/Efbemalenogastim alfa-vuxw.
- Use of Pegfilgrastim/Eflapregastim/Efbemalenogastim alfa-vuxw in myeloid malignancies or MDS, except for members with AML/ALL in remission who are receiving consolidation chemotherapy (e.g., HIDAC- High Dose Ara C).
- Dosing exceeds single dose limit for a long acting MGF (pegfilgrastim product) 6 mg or Eflapregastim 13.2 mg or Efbemalenogastim alfa-vuxw 20 mg.
- Dosing exceeds single dose limit for a short acting MGF (filgrastim product) 5 mcg/kg/day (rounded down to the nearest vial size in doses of 300 mcg for less than or equal to 60 kg or 480 mcg for greater than 60 kg), except when MGF is being used as a part of stem cell collection.
- Dosing exceeds single dose limit for Leukine (sargramostim) 250 mcg/m²/day (SC) or 500 mcg/m²/day (IV).

- Investigational use of Myeloid Growth Factors [Neupogen (filgrastim), Releuko (filgrastim-ayow), Granix (tbo-filgrastim), Sargramostim (leukine), Zarxio (filgrastim-sndz), Nivestym (filgrastim-aafi), Nypozi (filgrastim-txid), Neulasta/Neulasta Onpro Kit (pegfilgrastim), Fulphila (pegfilgrastim-jmdb), Udenyca (pegfilgrastim-cbqv), Ziextenzo (pegfilgrastim-bmez, Nyvepria (pegfilgrastim-apgf), Fylnetra (pegfilgrastim-pbbk), Stimufend (pegfilgrastim-fpgk), Rolvedon (eflapegrastim), and Ryzneuta (efbemalenograstim alfa-vuxw)] with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community. Sufficient evidence that is not supported by CMS recognized compendia or acceptable peer reviewed literature is defined as any of the following:
 - Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence.
 - Whether the administered chemotherapy/biologic therapy/immune therapy/targeted therapy/other oncologic therapy regimen is adequately represented in the published evidence.
 - Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. Generally, the definitions of Clinically Meaningful outcomes are those recommended by ASCO, e.g., Hazard Ratio of less than 0.80 and the recommended survival benefit for OS and PFS should be at least 3 months.
 - Whether the experimental design, considering the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover).
 - That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs.
 - That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs.
 - That abstracts (including meeting abstracts) without the full article from the approved peer-reviewed journals lack supporting clinical evidence for determining accepted uses of drugs.

CODING AND STANDARDS

Codes

- J1442 - Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram
- J1447 - Injection, tbo-filgrastim, 1 microgram
- J1449 - Injection, eflapegrastim-xnst, 0.1 mg
- J2506 - Injection, pegfilgrastim, excludes biosimilar, 0.5 mg
- J2820 - Injection, sargramostim (gm-csf), 50 mcg
- J9361 - Injection, efbemalenograstim alfa-vuxw, 0.5 mg
- Q5101 - Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram

- Q5108 - Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg
- Q5110 - Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
- Q5111 - Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg
- Q5120 - Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg
- Q5122 - Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg
- Q5125 - Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram
- Q5127 - Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg
- Q5130 - Injection, pegfilgrastim-pbbk (flyneta), biosimilar, 0.5 mg
- Q5148 - Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram

Applicable Lines of Business

☐	CHIP (Children's Health Insurance Program)
☒	Commercial
☒	Exchange/Marketplace
☒	Medicaid
☐	Medicare Advantage

POLICY HISTORY

Date	Summary
May 2025	● Converted to new Evolent guideline template ● This guideline replaces UM ONC_1072 Myeloid Growth Factors (MGFs) ● Updated indication section ● Updated references
August 2024	● Added new long-acting MGF "Ryzneuta (efbemalenograstim alfa-vuxw)" to policy ● Added new biosimilar "Nypozi (filgrastim-txid)" to policy ● Added new references

LEGAL AND COMPLIANCE

Guideline Approval

Committee

Reviewed / Approved by Evolent Specialty Clinical Guideline Review Committee

Disclaimer

Evolent Clinical Guidelines do not constitute medical advice. Treating health care professionals are solely responsible for diagnosis, treatment, and medical advice. Evolent uses Clinical Guidelines in accordance with its contractual obligations to provide utilization management. Coverage for services varies for individual members according to the terms of their health care coverage or government program. Individual members' health care coverage may not utilize some Evolent Clinical Guidelines. Evolent clinical guidelines contain guidance that requires prior authorization and service limitations. A list of procedure codes, services or drugs may not be all inclusive and does not imply that a service or drug is a covered or non-covered service or drug. Evolent reserves the right to review and update this Clinical Guideline in its sole discretion. Notice of any changes shall be provided as required by applicable provider agreements and laws or regulations. Members should contact their Plan customer service representative for specific coverage information.

REFERENCES

1. Hartmann LC, et al. Granulocyte colony-stimulating factor in severe chemotherapy-induced febrile neutropenia. *N Engl J Med*. 1997 Jun 19;336(25):1776-80. doi: 10.1056/NEJM199706193362502.
2. Singh R, Heisey H, Elsayed AG, Tirona MT. Adequate neutrophil responses and non-inferior clinical outcomes can be achieved by a two-day course of low-dose filgrastim: a retrospective single institution experience. *Cureus*. 2017 Dec 19;9(12):e1968. doi: 10.7759/cureus.1968.
3. Brusamolino E, et al. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. *Haematologica*. 2006 Apr;91(4):496-502.
4. Burstein HJ, et al. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. *J Clin Oncol*. 2005 Nov 20;23(33):8340-7. doi: 10.1200/JCO.2005.02.8621.
5. Jones RL, et al. A randomized pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer. *Br J Cancer*. 2009 Jan 27;100(2):305-10. doi: 10.1038/sj.bjc.6604862.
6. Hecht JR, et al. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. *Clin Colorectal Cancer*. 2010 Apr;9(2):95-101. doi: 10.3816/CCC.2010.n.013.
7. Smith T et al. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline. *J Clin Oncol*. 2006 Jul 1;24(19):3187-205. doi: 10.1200/JCO.2006.06.4451.
8. NCCN Clinical Practice Guidelines in Oncology: Hematopoietic Growth Factors. January, 2025.
9. Ryzneuta prescribing information. Evive Biotechnology Singapore PTE. LTD, Singapore 2023
10. Nypozi prescribing information. Tanvex BioPharma USA, Inc., San Diego, CA 2024
11. Rolvedon prescribing information. Spectrum Pharmaceuticals, Inc. Lake Forest, IL 2023.
12. Flyneta prescribing information. Kashiv BioSciences, LLC. Piscataway, NJ 2025.
13. Stimufend prescribing information. Fresenius Kabi USA, LLC. Lake Zurich IL 2023.
14. Releuko prescribing information. Kashiv BioSciences, LLC. Piscataway, NJ 2025.
15. Zarxio prescribing information. Sandoz Inc. Princeton, NJ2024.
16. Granix prescribing information. Teva Pharmaceuticals USA, Inc. North Wales, PA2023.
17. Neupogen prescribing information. Amgen, Inc. Thousand Oaks, CA 2025.
18. Neulasta prescribing information. Amgen, Inc. Thousand Oaks, CA 2025.
19. Leukine prescribing information. Partner Therapeutics, Inc. Lexington, MA 2018.
20. Nyvepria prescribing information. Hospira, Inc., a Pfizer Company. Lake Forest, IL 2023.
21. Fulphila prescribing information. Biocon Biologics Inc. Cambridge, MA 2023.
22. Nivestym prescribing information. Hospira, Inc., a Pfizer Company. Lake Forest, IL 2024.
23. Udenyca prescribing information. Coherus BioSciences, Inc., Redwood City, CA 2023.
24. Ziextenzo prescribing information. Sandoz Inc. Princeton, NJ 2022.
25. Clinical Pharmacology Elsevier Gold Standard 2025.
26. Micromedex® Healthcare Series: Micromedex Drugdex Ann Arbor, Michigan 2025.

27. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium 2025.
28. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs. Bethesda, MD 2025.
29. Ellis LM, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. *J Clin Oncol*. 2014 Apr 20;32(12):1277-80.
30. Medicare Benefit Policy Manual Chapter 15 Covered Medical and Other Health Services:
<https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf>.
31. Current and Resolved Drug Shortages and Discontinuations Reported to the FDA:
<http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm>.

ATTACHMENT A: LOW RISK REGIMENS (LESS THAN 10% FN RISK)

Regimen Name
(DARBEPOETIN ALFA OR EPOETIN ALFA) + LENALIDOMIDE
ABEMACICLIB
ABEMACICLIB + ANASTROZOLE
ABEMACICLIB + EXEMESTANE
ABEMACICLIB + FULVESTRANT
ABEMACICLIB + FULVESTRANT + GOSERELIN
ABEMACICLIB + FULVESTRANT + LEUPROLIDE
ABEMACICLIB + FULVESTRANT + TRIPTORELIN
ABEMACICLIB + LETROZOLE
ABIRATERONE + PREDNISONE
AC (DOXORUBICIN + CYCLOPHOSPHAMIDE) FOLLOWED BY PACLITAXEL
ACALABRUTINIB
ADO-TRASTUZUMAB EMTANSINE (KADCYLA)
AFATINIB
AFATINIB + CETUXIMAB
ALECTINIB
ALPELISIB + FULVESTRANT
ALTRETAMINE
AMIVANTAMAB-VMJW
ANASTROZOLE
ANASTROZOLE + GOSERELIN ACETATE
ANASTROZOLE + LAPATINIB
ANASTROZOLE + LAPATINIB + TRASTUZUMAB
ANASTROZOLE + LEUPROLIDE ACETATE
ANASTROZOLE + TRASTUZUMAB
ANASTROZOLE + TRIPTORELIN PAMOATE
ANTITHYMOCYTE GLOBULIN (ATG)
ANTITHYMOCYTE GLOBULIN (ATG) + PREDNISONE
APALUTAMIDE
ARSENIC TRIOXIDE
ASCIMINIB

ATEZOLIZUMAB
ATEZOLIZUMAB + BEVACIZUMAB
ATEZOLIZUMAB + PACLITAXEL PROTEIN BOUND
ATG + CYCLOSPORINE + PREDNISONE
ATRA + 6-MERCAPTOPURINE + METHOTREXATE
ATRA + ARSENIC TRIOXIDE
ATRA + ARSENIC TRIOXIDE + DAUNORUBICIN
ATRA + ARSENIC TRIOXIDE + IDARUBICIN
ATRA + CYTARABINE + DAUNORUBICIN
ATRA + CYTARABINE + IDARUBICIN
ATRA + DAUNORUBICIN
ATRA + GEMTUZUMAB
ATRA + IDARUBICIN
ATRA + MITOXANTRONE
AVELUMAB
AVELUMAB + AXITINIB
AXITINIB
BACILLUS CALMETTE-GUERIN (BCG LIVE) INTRAVESICAL
BELANTAMAB MAFODOTIN-BLMF
BELZUTIFAN
BENDAMUSTINE + OFATUMUMAB
BENDAMUSTINE + STEROID
BEVACIZUMAB
BEVACIZUMAB + ATEZOLIZUMAB
BEVACIZUMAB + CARBOPLATIN + GEMCITABINE
BEVACIZUMAB + CARBOPLATIN + PACLITAXEL
BEVACIZUMAB + CARMUSTINE
BEVACIZUMAB + DOXORUBICIN HCL LIPOSOME (DOXIL)
BEVACIZUMAB + ERLOTINIB
BEVACIZUMAB + EVEROLIMUS
BEVACIZUMAB + INTERFERON ALFA
BEVACIZUMAB + IRINOTECAN
BEVACIZUMAB + LOMUSTINE
BEVACIZUMAB + PACLITAXEL

BEVACIZUMAB + PACLITAXEL + CISPLATIN
BEVACIZUMAB + PACLITAXEL + TOPOTECAN
BEVACIZUMAB + PEMETREXED
BEVACIZUMAB + TEMOZOLOMIDE
BICALUTAMIDE
BORTEZOMIB
BORTEZOMIB + BENDAMUSTINE + STEROID
BORTEZOMIB + DOXORUBICIN + STEROID
BORTEZOMIB + DOXORUBICIN LIPOSOMAL + STEROID
BORTEZOMIB + LENALIDOMIDE (MAINTENANCE)
BORTEZOMIB + LENALIDOMIDE + STEROID
BORTEZOMIB + RITUXIMAB
BORTEZOMIB + STEROID
BORTEZOMIB + THALIDOMIDE + STEROID (VTD)
BOSUTINIB
BRENTUXIMAB
BREXUCABTAGENE AUTOLEUCEL
BRIGATINIB
CABOZANTINIB
CABOZANTINIB + NIVOLUMAB
CALGB 8811 CNS PROPHYLAXIS (METHOTREXATE) AND INTERIM MAINTAINANCE (METHOTREXATE AND MERCAPTOPURINE)
CALGB 8811 MAINTENANCE (VINCRISTINE + PREDNISONE + METHOTREXATE + MERCAPTOPURINE)
CAPECITABINE
CAPECITABINE + BEVACIZUMAB
CAPECITABINE + CISPLATIN
CAPECITABINE + CISPLATIN + PEMBROLIZUMAB
CAPECITABINE + GEMCITABINE
CAPECITABINE + MITOMYCIN
CAPECITABINE + OXALIPLATIN
CAPECITABINE + OXALIPLATIN (CAPEOX)
CAPECITABINE + OXALIPLATIN (CAPEOX) + NIVOLUMAB
CAPECITABINE + OXALIPLATIN (CAPEOX) + PEMBROLIZUMAB
CAPECITABINE + OXALIPLATIN + BEVACIZUMAB (CAPEOX + BEVACIZUMAB 5MG/KG)

CAPECITABINE + OXALIPLATIN + BEVACIZUMAB (CAPEOX + BEVACIZUMAB 7.5MG/KG)
CAPECITABINE + OXALIPLATIN + TRASTUZUMAB
CAPECITABINE + OXALIPLATIN + TRASTUZUMAB + PEMBROLIZUMAB
CAPECITABINE + RADIATION
CAPECITABINE + TEMOZOLOMIDE
CAPECITABINE + TRASTUZUMAB
CAPMATINIB
CARBOPLATIN
CARBOPLATIN + CETUXIMAB
CARBOPLATIN + DOXORUBICIN HCL LIPOSOME (DOXIL)
CARBOPLATIN + FLUOROURACIL + CETUXIMAB
CARBOPLATIN + FLUOROURACIL + PEMBROLIZUMAB FOLLOWED BY PEMBROLIZUMAB
CARBOPLATIN + IRINOTECAN
CARBOPLATIN + PACLITAXEL (Anal, Breast, Cervical, and Ovarian Cancer)
CARBOPLATIN + PACLITAXEL (WEEKLY WITH RADIATION)
CARBOPLATIN + PACLITAXEL (WEEKLY)
CARBOPLATIN + PACLITAXEL + BEVACIZUMAB
CARBOPLATIN + PACLITAXEL + CETUXIMAB
CARBOPLATIN + PACLITAXEL + TRASTUZUMAB
CARBOPLATIN + PACLITAXEL PROTEIN BOUND
CARBOPLATIN + PACLITAXEL PROTEIN BOUND (ABRAXANE)
CARBOPLATIN + PACLITAXEL PROTEIN BOUND + ATEZOLIZUMAB FOLLOWED BY ATEZOLIZUMAB
CARBOPLATIN + PACLITAXEL PROTEIN BOUND + PEMBROLIZUMAB FOLLOWED BY PEMBROLIZUMAB
CARBOPLATIN + PEMETREXED
CARBOPLATIN + PEMETREXED + BEVACIZUMAB
CARBOPLATIN + PEMETREXED + PEMBROLIZUMAB
CARBOPLATIN + PEMETREXED + PEMBROLIZUMAB FOLLOWED BY PEMBROLIZUMAB +/- PEMETREXED
CARBOPLATIN + TRASTUZUMAB
CARFILZOMIB
CARFILZOMIB + LENALIDOMIDE + STEROID
CARFILZOMIB + POMALIDOMIDE + STEROID

CARFILZOMIB + STEROID
CARMUSTINE (BCNU)
CEMIPLIMAB-RWLC
CERITINIB
CETUXIMAB
CHLORAMBUCIL
CHLORAMBUCIL + OBINUTUZUMAB
CHLORAMBUCIL + OFATUMUMAB
CHLORAMBUCIL + RITUXIMAB
CISPLATIN
CISPLATIN + CAPECITABINE
CISPLATIN + CETUXIMAB
CISPLATIN + DOXORUBICIN
CISPLATIN + DOXORUBICIN HCL LIPOSOME (DOXIL)
CISPLATIN + FLUOROURACIL
CISPLATIN + FLUOROURACIL + CETUXIMAB
CISPLATIN + FLUOROURACIL + LEUCOVORIN
CISPLATIN + FLUOROURACIL + PEMBROLIZUMAB FOLLOWED BY PEMBROLIZUMAB
CISPLATIN + FLUOROURACIL + RADIATION
CISPLATIN + FLUOROURACIL + TRASTUZUMAB + PEMBROLIZUMAB
CISPLATIN + METHOTREXATE + VINBLASTINE (CMV)
CISPLATIN + PACLITAXEL + CETUXIMAB
CISPLATIN + PACLITAXEL + PEMBROLIZUMAB
CISPLATIN + PACLITAXEL + RADIATION
CISPLATIN + PACLITAXEL PROTEIN BOUND + PEMBROLIZUMAB FOLLOWED BY PEMBROLIZUMAB
CISPLATIN + PEMETREXED
CISPLATIN + PEMETREXED + BEVACIZUMAB
CISPLATIN + PEMETREXED + PEMBROLIZUMAB
CISPLATIN + PEMETREXED + PEMBROLIZUMAB FOLLOWED BY PEMBROLIZUMAB +/- PEMETREXED
CISPLATIN + RADIATION
CISPLATIN + TRASTUZUMAB
CISPLATIN + VINBLASTINE
COPANLISIB

CRIZOTINIB
CYCLOPHOSPHAMIDE
CYCLOPHOSPHAMIDE (IV)
CYCLOPHOSPHAMIDE (IV) + BORTEZOMIB + STEROID
CYCLOPHOSPHAMIDE (IV) + CARFILZOMIB + STEROID
CYCLOPHOSPHAMIDE (IV) + METHOTREXATE + FLUOROURACIL (CMF)
CYCLOPHOSPHAMIDE (ORAL)
CYCLOPHOSPHAMIDE (ORAL) + BORTEZOMIB + STEROID
CYCLOPHOSPHAMIDE (ORAL) + CARFILZOMIB + STEROID
CYCLOPHOSPHAMIDE (ORAL) + LENALIDOMIDE + STEROID
CYCLOPHOSPHAMIDE + BEVACIZUMAB
CYCLOPHOSPHAMIDE + ETOPOSIDE (IV ONLY) + VINCRISTINE + PREDNISONE (CEOP)
CYCLOPHOSPHAMIDE + ETOPOSIDE (IV TO ORAL) + VINCRISTINE + PREDNISONE (CEOP)
CYCLOPHOSPHAMIDE + ETOPOSIDE (IV) + PROCARBAZINE + PREDNISONE (CEPP)
CYCLOPHOSPHAMIDE + ETOPOSIDE + VINCRISTINE + PREDNISONE (CEOP)
CYCLOPHOSPHAMIDE + RITUXIMAB
CYCLOPHOSPHAMIDE + TRASTUZUMAB
CYCLOPHOSPHAMIDE + VINCRISTINE + PROCARBAZINE + PREDNISONE (C-MOPP)
CYTARABINE
CYTARABINE + DAUNORUBICIN
DABRAFENIB
DABRAFENIB + TRAMETINIB
DACARBAZINE
DACOMITINIB
DARATUMUMAB
DARATUMUMAB + BORTEZOMIB + MELPHALAN + STEROID
DARATUMUMAB + BORTEZOMIB + STEROID
DARATUMUMAB + CARFILZOMIB + STEROID
DARATUMUMAB + CYCLOPHOSPHAMIDE + BORTEZOMIB + STEROID
DARATUMUMAB + LENALIDOMIDE + STEROID
DARATUMUMAB + POMALIDOMIDE + STEROID
DARATUMUMAB + LENALIDOMIDE + BORTEZOMIB + STEROID
DARATUMUMAB + LENALIDOMIDE + CARFILZOMIB + STEROID

DARATUMUMAB+ THALIDOMIDE + BORTEZOMIB + STEROID
DARATUMUMAB + SELINEXOR + STEROID
DARBEPOETIN + LENALIDOMIDE
DARBEPOETIN ALFA + LENALIDOMIDE
DAROLUTAMIDE
DASATINIB
DEGARELIX
DEGARELIX + ABIRATERONE + STEROID
DEGARELIX + APALUTAMIDE
DEGARELIX + DOCETAXEL
DEGARELIX + ENZALUTAMIDE
DOCETAXEL (EVERY WEEK DOSING)
DOCETAXEL (FOLLOWING NEOADJUVANT/ADJUVANT CHEMOTHERAPY)
DOCETAXEL + CISPLATIN
DOCETAXEL + CISPLATIN (WITH RADIATION)
DOCETAXEL + OXALIPLATIN + FLUOROURACIL
DOCETAXEL + OXALIPLATIN + FLUOROURACIL + LEUCOVORIN
DOSTARLIMAB-GXLY
DOXORUBICIN + VINBLASTINE + DACARBAZINE (AVD)
DOXORUBICIN HCL LIPOSOME (DOXIL)
DOXORUBICIN INTRAVESICAL
DURVALUMAB
DURVALUMAB (FOR NON-SMALL CELL LUNG CANCER)
DURVALUMAB (FOR SMALL CELL LUNG CANCER)
DUVELISIB
ELOTUZUMAB + BORTEZOMIB + STEROID
ELOTUZUMAB + LENALIDOMIDE + STEROID
ELOTUZUMAB + POMALIDOMIDE + STEROID
EMFORTUMAB VEDOTIN-EJFV
ENASIDENIB
ENCORAFENIB + BINIMETINIB
ENCORAFENIB + CETUXIMAB
ENCORAFENIB + PANITUMUMAB
ENFORTUMAB VEDOTIN-EJFV

ENTRECTINIB
ENZALUTAMIDE
EPIRUBICIN
EPIRUBICIN + CYCLOPHOSPHAMIDE (EC)
EPOETIN + LENALIDOMIDE
EPOETIN ALFA + LENALIDOMIDE
EPOETIN ALFA-EPBX (RETACRIT) + LENALIDOMIDE
ERDAFITINIB
ERIBULIN
ERIBULIN + TRASTUZUMAB
ERLOTINIB
ERLOTINIB + BEVACIZUMAB
ERLOTINIB + RAMUCIRUMAB
ETOPOSIDE (IV)
ETOPOSIDE (ORAL)
EVEROLIMUS
EVEROLIMUS + EXEMESTANE
EVEROLIMUS + FULVESTRANT
EVEROLIMUS + LENVATINIB
EVEROLIMUS + TAMOXIFEN
EVEROLIMUS + IMATINIB/ SUNITINIB/ REGORAFENIB
EXEMESTANE
EXEMESTANE + GOSERELIN ACETATE
EXEMESTANE + LAPATINIB
EXEMESTANE + LAPATINIB + TRASTUZUMAB
EXEMESTANE + LEUPROLIDE ACETATE
EXEMESTANE + TRASTUZUMAB
EXEMESTANE + TRIPTORELIN PAMOATE
FAM-TRASTUZUMAB DERUXTECAN-NXKI
FLUDARABINE + RITUXIMAB
FLUOROURACIL
FLUOROURACIL + CISPLATIN
FLUOROURACIL + CISPLATIN + PEMBROLIZUMAB
FLUOROURACIL + CISPLATIN + TRASTUZUMAB + PEMBROLIZUMAB

FLUOROURACIL + HYDROXYUREA
FLUOROURACIL + LEUCOVORIN
FLUOROURACIL + LEUCOVORIN + BEVACIZUMAB
FLUOROURACIL + LEUCOVORIN + OXALIPLATIN
FLUOROURACIL + MITOMYCIN
FLUOROURACIL + MITOMYCIN + RADIATION
FLUOROURACIL + RADIATION
FLUOROURACIL +/- LEUCOVORIN
FLUTAMIDE
FULVESTRANT
FULVESTRANT + ANASTROZOLE
FULVESTRANT + GOSERELIN
FULVESTRANT + LETROZOLE
FULVESTRANT + LEUPROLIDE
FULVESTRANT + TRASTUZUMAB
FULVESTRANT + TRIPTORELIN
GEFITINIB
GEMCITABINE (Head and Neck Cancer)
GEMCITABINE + OXALIPLATIN + PACLITAXEL
GEMCITABINE + CAPECITABINE (GEM-CAP)
GEMCITABINE + CARBOPLATIN (Bladder)
GEMCITABINE + DACARBAZINE
GEMCITABINE + ERLOTINIB
GEMCITABINE + OXALIPLATIN
GEMCITABINE + OXALIPLATIN (GEMOX)
GEMCITABINE + PACLITAXEL
GEMCITABINE + PACLITAXEL (GT)
GEMCITABINE + PACLITAXEL + OXALIPLATIN
GEMCITABINE + PACLITAXEL PROTEIN BOUND
GEMCITABINE + TRASTUZUMAB
GEMCITABINE INTRAVESICAL
GEMTUZUMAB
GOSERELIN ACETATE
GOSERELIN ACETATE + ABIRATERONE + STEROID

GOSERELIN ACETATE + APALUTAMIDE
GOSERELIN ACETATE + BICALUTAMIDE
GOSERELIN ACETATE + BICALUTAMIDE + DOCETAXEL
GOSERELIN ACETATE + DOCETAXEL
GOSERELIN ACETATE + ENZALUTAMIDE
GOSERELIN ACETATE + FLUTAMIDE
GOSERELIN ACETATE + FLUTAMIDE + DOCETAXEL
GOSERELIN ACETATE + NILUTAMIDE
GOSERELIN ACETATE + NILUTAMIDE + DOCETAXEL
HIGH DOSE INTERLEUKIN-2
IBRITUMOMAB TIUXETAN
IBRUTINIB
IBRUTINIB + OBINUTUZUMAB
IBRUTINIB + RITUXIMAB
IBRUTINIB + RITUXIMAB + LENALIDOMIDE
IBRUTINIB + VENETOCLAX
IDELALISIB
IDELALISIB + RITUXIMAB
IFOSFAMIDE + MESNA
IFOSFAMIDE + MESNA (IV/ORAL)
IMATINIB
IMATINIB (HIGH DOSE 600-800MG/DAY)
INFIGRATINIB
INTERLEUKIN-2
IPILIMUMAB
IRINOTECAN (Esophageal Cancer)
IRINOTECAN + BEVACIZUMAB 5MG/KG
IRINOTECAN + CETUXIMAB
IRINOTECAN + CISPLATIN (Ovarian Cancer)
IRINOTECAN + FLUOROURACIL + LEUCOVORIN (IFL)
IRINOTECAN + LEUCOVORIN + FLUOROURACIL
IRINOTECAN + OXALIPLATIN (IROX)
IRINOTECAN + OXALIPLATIN + BEVACIZUMAB (IROX + BEVACIZUMAB 5MG/KG)
IRINOTECAN + PANITUMUMAB

IRINOTECAN + RAMUCIRUMAB
IRINOTECAN LIPOSOME + FLUOROURACIL + LEUCOVORIN
ISATUXIMAB + CARFILZOMIB + STEROID
ISATUXIMAB + POMALIDOMIDE + STEROID
IT CYTARABINE
IT CYTARABINE + HYDROCORTISONE
IT METHOTREXATE
IT METHOTREXATE + CYTARABINE
IT METHOTREXATE + CYTARABINE + HYDROCORTISONE
IVOSIDENIB
IXABEPILONE
IXABEPILONE + TRASTUZUMAB
IXAZOMIB
IXAZOMIB + LENALIDOMIDE + STEROID
IXAZOMIB + POMALIDOMIDE + STEROID
IXAZOMIB + STEROID
LAPATINIB + CAPECITABINE
LAPATINIB + TRASTUZUMAB
LAROTRECTINIB
LENALIDOMIDE
LENALIDOMIDE + BENDAMUSTINE + STEROID
LENALIDOMIDE + OBINUTUZUMAB
LENALIDOMIDE + RITUXIMAB
LENALIDOMIDE + STEROID
LENVATINIB
LENVATINIB + PEMBROLIZUMAB
LETROZOLE
LETROZOLE + GOSERELIN ACETATE
LETROZOLE + LAPATINIB
LETROZOLE + LAPATINIB + TRASTUZUMAB
LETROZOLE + LEUPROLIDE ACETATE
LETROZOLE + TRASTUZUMAB
LETROZOLE + TRIPTORELIN PAMOATE
LEUPROLIDE + BICALUTAMIDE

LEUPROLIDE + BICALUTAMIDE + DOCETAXEL
LEUPROLIDE + DOCETAXEL
LEUPROLIDE + FLUTAMIDE
LEUPROLIDE + NILUTAMIDE
LEUPROLIDE ACETATE
LEUPROLIDE ACETATE + ABIRATERONE + STEROID
LEUPROLIDE ACETATE + APALUTAMIDE
LEUPROLIDE ACETATE + ENZALUTAMIDE
LEUPROLIDE ACETATE + FLUTAMIDE + DOCETAXEL
LEUPROLIDE ACETATE + NILUTAMIDE + DOCETAXEL
LEUPROLIDE MESYLATE
LISOCABTAGENE MARALEUCEL
LOMUSTINE
LORLATINIB
LURBINECTEDIN
LUSPATERCEPT-AAMT
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN INJECTION
MARGETUXIMAB-CMKB + CAPECITABINE
MARGETUXIMAB-CMKB + ERIBULIN
MARGETUXIMAB-CMKB + GEMCITABINE
MARGETUXIMAB-CMKB + VINORELBINE
MEDROXYPROGESTERONE (IM)
MEGESTROL ACETATE
MELPHALAN (ORAL)
METHOTREXATE
METHYLPREDNISOLONE + RITUXIMAB
MITOMYCIN INTRAVESICAL
MITOXANTRONE + PREDNISONE
MOBOCERTINIB
NERATINIB
NERATINIB + CAPECITABINE
NILOTINIB
NILUTAMIDE
NIRAPARIB

NIVOLUMAB
NIVOLUMAB + CISPLATIN + GEMCITABINE
NIVOLUMAB + CISPLATIN + PEMETREXED
NIVOLUMAB + IPILIMUMAB + CARBOPLATIN + PACLITAXEL
NIVOLUMAB + IPILIMUMAB + CARBOPLATIN + PEMETREXED
NIVOLUMAB + IPILIMUMAB + CISPLATIN + PEMETREXED
NIVOLUMAB + IPILIMUMAB FOLLOWED BY NIVOLUMAB
NIVOLUMAB + IPILIMUMAB
NIVOLUMAB/RELATLIMAB-RMBW
OBINUTUZUMAB
OBINUTUZUMAB + CYCLOPHOSPHAMIDE (IV)+ VINCRISTINE + PREDNISONE (G-CVP)
OLAPARIB
OLAPARIB + BEVACIZUMAB
OSIMERTINIB
OXALIPLATIN
OXALIPLATIN + CAPECITABINE
OXALIPLATIN + FLUOROURACIL
OXALIPLATIN + FLUOROURACIL + LEUCOVORIN
OXALIPLATIN + LEUCOVORIN + FLUOROURACIL (FOLFOX)
PACLITAXEL
PACLITAXEL (ALBUMIN-BOUND)
PACLITAXEL (IV) + CARBOPLATIN (IP) + PACLITAXEL (IP)
PACLITAXEL (IV) + CISPLATIN (IP) + PACLITAXEL (IP)
PACLITAXEL + BEVACIZUMAB
PACLITAXEL + CARBOPLATIN (Endometrial, Head and Neck Cancer)
PACLITAXEL + CARBOPLATIN + BEVACIZUMAB
PACLITAXEL + CARBOPLATIN + TRASTUZUMAB (PCH)
PACLITAXEL + CARBOPLATIN+ TRASTUZUMAB + PERTUZUMAB
PACLITAXEL + CISPLATIN (Head and Neck Cancer)
PACLITAXEL + PAZOPANIB
PACLITAXEL + TOPOTECAN
PACLITAXEL + TRASTUZUMAB
PACLITAXEL + TRASTUZUMAB + PERTUZUMAB
PACLITAXEL PROTEIN BOUND (ABRAXANE)

PACLITAXEL PROTEIN BOUND + TRASTUZUMAB
PALBOCICLIB + ANASTROZOLE
PALBOCICLIB + EXEMESTANE
PALBOCICLIB + FULVESTRANT
PALBOCICLIB + FULVESTRANT + GOSERELIN
PALBOCICLIB + FULVESTRANT + LEUPROLIDE
PALBOCICLIB + FULVESTRANT + TRIPTORELIN
PALBOCICLIB + LETROZOLE
PANITUMUMAB
PANOBINOSTAT + BORTEZOMIB + STEROID
PANOBINOSTAT + CARFILZOMIB
PANOBINOSTAT + LENALIDOMIDE + STEROID
PAZOPANIB
PEMBROLIZUMAB
PEMBROLIZUMAB + AXITINIB
PEMBROLIZUMAB + CARBOPLATIN + GEMCITABINE
PEMBROLIZUMAB + CETUXIMAB
PEMBROLIZUMAB + CISPLATIN + GEMCITABINE
PEMBROLIZUMAB + LENVATINIB
PEMBROLIZUMAB + PACLITAXEL
PEMBROLIZUMAB + PACLITAXEL PROTEIN BOUND
PEMBROLIZUMAB + PEMETREXED
PEMETREXED
PENTOSTATIN + CYCLOPHOSPHAMIDE + RITUXIMAB (PCR)
PERTUZUMAB / TRASTUZUMAB / HYALURONIDASE-ZZXF
POMALIDOMIDE
POMALIDOMIDE + BORTEZOMIB + STEROID
POMALIDOMIDE + CYCLOPHOSPHAMIDE (ORAL) + STEROID
POMALIDOMIDE + STEROID
PONATINIB
PRALSETINIB
PROCARBAZINE + LOMUSTINE + VINCRIStINE (PCV)
RADIUM 223
RAMUCIRUMAB

RAMUCIRUMAB + PACLITAXEL
REGORAFENIB
RELUGOLIX
RIBOCICLIB + ANASTROZOLE
RIBOCICLIB + EXEMESTANE
RIBOCICLIB + FULVESTRANT
RIBOCICLIB + LETROZOLE
RITUXIMAB
RITUXIMAB + CYCLOPHOSPHAMIDE (IV)+ VINBLASTINE + PREDNISONE
RITUXIMAB + CYCLOPHOSPHAMIDE (IV)+ VINCRIStINE + PREDNISONE (R-CVP)
RITUXIMAB + CYCLOPHOSPHAMIDE + ETOPOSIDE (IV ONLY) + VINCRIStINE + PREDNISONE (R-CEOP)
RITUXIMAB + CYCLOPHOSPHAMIDE + ETOPOSIDE (IV TO ORAL) + VINCRIStINE + PREDNISONE (R-CEOP)
RITUXIMAB + CYCLOPHOSPHAMIDE + ETOPOSIDE + PROCARBAZINE + PREDNISONE (R-CEPP)
RITUXIMAB + CYCLOPHOSPHAMIDE + ETOPOSIDE +VINCRIStINE + PREDNISONE (R-CEOP)
RITUXIMAB + GEMCITABINE + OXALIPLATIN (R-GEMOX)
RITUXIMAB + LENALIDOMIDE
RUCAPARIB
SELINEXOR + BORTEZOMIB + STEROID
SELINEXOR + STEROID
SELPERCATINIB
SIPULEUCeL-T
SORAFENIB
SOTORASIB
SUNITINIB
TALAZOPARIB
TAMOXIFEN
TAMOXIFEN + GOSERELIN ACETATE
TAMOXIFEN + LEUPROLIDE ACETATE
TAMOXIFEN + TRASTUZUMAB
TAMOXIFEN +TRIPTORELIN PAMOATE
TAZEMETOSTAT
TEMOZOLOMIDE

TEMSIROLIMUS
TEPOTINIB
TISOTUMAB VEDOTIN-TFTV
TIVOZANIB
TOREMIFENE
TRASTUZUMAB
TRASTUZUMAB (UP TO 52 WEEKS FOLLOWING NEOADJUVANT/ADJUVANT TRASTUZUMAB CHEMOTHERAPY)
TRASTUZUMAB [UP TO 52 WEEKS FOLLOWING TCH (DOCETAXEL/CARBOPLATIN/TRASTUZUMAB) CHEMOTHERAPY]
TRASTUZUMAB + CAPECITABINE + CISPLATIN
TRASTUZUMAB + CISPLATIN + CAPECITABINE
TRASTUZUMAB + CISPLATIN + FLUOROURACIL
TRASTUZUMAB + FLUOROURACIL + CISPLATIN
TRASTUZUMAB + PERTUZUMAB
TRASTUZUMAB + PERTUZUMAB (UP TO 52 WEEKS FOLLOWING NEOADJUVANT/ADJUVANT TRASTUZUMAB AND PERTUZUMAB CHEMOTHERAPY)
TRETINOIN + 6-MERCAPTOPURINE + METHOTREXATE
TRETINOIN + ARSENIC TRIOXIDE
TRETINOIN + ARSENIC TRIOXIDE + DAUNORUBICIN
TRETINOIN + ARSENIC TRIOXIDE + IDARUBICIN
TRETINOIN + CYTARABINE + DAUNORUBICIN
TRETINOIN + CYTARABINE + IDARUBICIN
TRETINOIN + DAUNORUBICIN
TRETINOIN + GEMTUZUMAB
TRETINOIN + IDARUBICIN
TRETINOIN + MITOXANTRONE
TRIFLURIDINE/TIPIRACIL
TRIPTORELIN PAMOATE
TRIPTORELIN PAMOATE + ABIRATERONE + STEROID
TRIPTORELIN PAMOATE + APALUTAMIDE
TRIPTORELIN PAMOATE + BICALUTAMIDE
TRIPTORELIN PAMOATE + BICALUTAMIDE + DOCETAXEL
TRIPTORELIN PAMOATE + DOCETAXEL
TRIPTORELIN PAMOATE + ENZALUTAMIDE
TRIPTORELIN PAMOATE + FLUTAMIDE

TRIPTORELIN PAMOATE + FLUTAMIDE + DOCETAXEL
TRIPTORELIN PAMOATE + NILUTAMIDE
TRIPTORELIN PAMOATE + NILUTAMIDE + DOCETAXEL
TUCATINIB + CAPECITABINE + TRASTUZUMAB
UMBRALISIB
VALRUBICIN INTRAVESICAL
VEMURAFENIB
VEMURAFENIB + COBIMETINIB
VENETOCLAX
VENETOCLAX + OBINUTUZUMAB
VENETOCLAX + RITUXIMAB
VINCRISTINE + DEXAMETHASONE
VINCRISTINE + DEXAMETHASONE + IMATINIB
VINCRISTINE + METHOTREXATE + 6-MERCAPTOPYRIMIDINE ± PREDNISONE
VINCRISTINE + METHOTREXATE + 6-MERCAPTOPYRIMIDINE ± PREDNISONE + IMATINIB
VINCRISTINE LIPOSOME
VINORELBINE
ZANUBRUTINIB

ATTACHMENT B: INTERMEDIATE RISK REGIMENS (10% TO 20% FN RISK)

Regimen Name
AC (DOXORUBICIN + CYCLOPHOSPHAMIDE) FOLLOWED BY DOCETAXEL + TRASTUZUMAB
AC (DOXORUBICIN + CYCLOPHOSPHAMIDE) FOLLOWED BY DOCETAXEL + TRASTUZUMAB + PERTUZUMAB
AC (DOXORUBICIN + CYCLOPHOSPHAMIDE) FOLLOWED BY PACLITAXEL + TRASTUZUMAB
AC (DOXORUBICIN + CYCLOPHOSPHAMIDE) FOLLOWED BY PACLITAXEL + TRASTUZUMAB + PERTUZUMAB
ATEZOLIZUMAB + CARBOPLATIN + ETOPOSIDE FOLLOWED BY ATEZOLIZUMAB
BENDAMUSTINE
BENDAMUSTINE + OBINUTUZUMAB
BENDAMUSTINE + RITUXIMAB
BLEOMYCIN + CISPLATIN + ETOPOSIDE
BORTEZOMIB + RITUXIMAB + CYCLOPHOSPHAMIDE + DOXORUBICIN + PREDNISONE (VR-CAP)
BRENTUXIMAB + BENDAMUSTINE
CABAZITAXEL + CARBOPLATIN + STEROID
CABAZITAXEL + PREDNISONE
CARBOPLATIN + DOCETAXEL
CARBOPLATIN + ETOPOSIDE
CARBOPLATIN + GEMCITABINE
CARBOPLATIN + PACLITAXEL (EVERY 3 WEEKS)
CARBOPLATIN + PACLITAXEL + PEMBROLIZUMAB
CARBOPLATIN + PACLITAXEL + PEMBROLIZUMAB FOLLOWED BY PEMBROLIZUMAB
CILTACABTAGENE AUTOLEUCEL
CISPLATIN + DOCETAXEL (Lung and Ovarian Cancer)
CISPLATIN + ETOPOSIDE (Bladder, Lung, Prostate, Testicular)
CISPLATIN + GEMCITABINE
CISPLATIN + IRINOTECAN (Lung Cancer)
CISPLATIN + PACLITAXEL (Cervical and Lung Cancer)
CISPLATIN + TOPOTECAN
CISPLATIN + VINORELBINE
CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP)

DAROLUTAMIDE + DOCETAXEL
DOCETAXEL (EVERY 3 WEEKS)
DOCETAXEL + CARBOPLATIN
DOCETAXEL + CISPLATIN + FLUOROURACIL (DCF)- Esophageal Cancer
DOCETAXEL + CISPLATIN + FLUOROURACIL (MODIFIED DCF)
DOCETAXEL + OXALIPLATIN + FLUOROURACIL (MODIFIED DCF)
DOCETAXEL + TRASTUZUMAB
DOCETAXEL + TRASTUZUMAB + PERTUZUMAB (THP)
DOXORUBICIN + BLEOMYCIN + VINBLASTINE + DACARBAZINE (ABVD)
DOXORUBICIN + CISPLATIN + PACLITAXEL (TAP)
DOXORUBICIN + CYCLOPHOSPHAMIDE (AC)
DOXORUBICIN/EPIRUBICIN + CYCLOPHOSPHAMIDE + PEMBROLIZUMAB
DURVALUMAB + CARBOPLATIN + ETOPOSIDE FOLLOWED BY DURVALUMAB
DURVALUMAB + CISPLATIN + ETOPOSIDE FOLLOWED BY DURVALUMAB
DURVALUMAB + CISPLATIN + GEMCITABINE FOLLOWED BY DURVALUMAB
FLUOROURACIL + EPIRUBICIN + CYCLOPHOSPHAMIDE (IV) FOLLOWED BY PERTUZUMAB + TRASTUZUMAB + DOCETAXEL
FLUOROURACIL + EPIRUBICIN + CYCLOPHOSPHAMIDE (IV) FOLLOWED BY PERTUZUMAB + TRASTUZUMAB + PACLITAXEL
FLUOROURACIL + LEUCOVORIN + OXALIPLATIN + DOCETAXEL (FLOT)
FLUOROURACIL + LEUCOVORIN + IRINOTECAN (FOLFIRI)
FLUOROURACIL + LEUCOVORIN + IRINOTECAN (FOLFIRI) + RAMUCIRUMAB
FLUOROURACIL + LEUCOVORIN + IRINOTECAN (FOLFIRI) + ZIV-AFLIBERCEPT
FLUOROURACIL + LEUCOVORIN + IRINOTECAN + BEVACIZUMAB (FOLFIRI + BEVACIZUMAB 5MG/KG)
FLUOROURACIL + LEUCOVORIN + IRINOTECAN + CETUXIMAB (FOLFIRI + CETUXIMAB)
FLUOROURACIL + LEUCOVORIN + IRINOTECAN + PANITUMUMAB (FOLFIRI + PANITUMUMAB)
FLUOROURACIL + LEUCOVORIN + OXALIPLATIN (FLOX)
FLUOROURACIL + LEUCOVORIN + OXALIPLATIN (FOLFOX)
FLUOROURACIL + LEUCOVORIN + OXALIPLATIN (FOLFOX) + NIVOLUMAB
FLUOROURACIL + LEUCOVORIN + OXALIPLATIN (FOLFOX) + PEMBROLIZUMAB
FLUOROURACIL + LEUCOVORIN + OXALIPLATIN + BEVACIZUMAB (FOLFOX + BEVACIZUMAB 5 MG/KG)
FLUOROURACIL + LEUCOVORIN + OXALIPLATIN + CETUXIMAB (FOLFOX + CETUXIMAB)
FLUOROURACIL + LEUCOVORIN + OXALIPLATIN + PANITUMUMAB (FOLFOX + PANITUMUMAB)
FLUOROURACIL + LEUCOVORIN + OXALIPLATIN + TRASTUZUMAB

FLUOROURACIL + MITOMYCIN
GEMCITABINE (Soft Tissue Sarcoma)
GEMCITABINE + CARBOPLATIN (Hepatobiliary Cancers)
GEMCITABINE + CISPLATIN
GEMCITABINE + CISPLATIN + DEXAMETHASONE (GCD)
GEMCITABINE + DEXAMETHASONE + CARBOPLATIN (GDP)
GEMCITABINE + DEXAMETHASONE + CISPLATIN (GDP)
GEMCITABINE + VINORELBINE
GEMCITABINE + VINORELBINE + LIPOSOMAL DOXORUBICIN (GVD)
IDECABTAGENE VICLEUCEL
IFOSFAMIDE + MESNA + PACLITAXEL
IXAZOMIB + CYCLOPHOSPHAMIDE + STEROID
OBINUTUZUMAB + BENDAMUSTINE
OBINUTUZUMAB + CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRIStINE + PREDNISONE (G-CHOP)
OMACETAXINE
OXALIPLATIN + FLUOROURACIL + LEUCOVORIN (FOLFOX)
OXALIPLATIN + IRINOTECAN + LEUCOVORIN + FLUOROURACIL (MODIFIED FOLFIRINOX)
PACLITAXEL + CARBOPLATIN (EVERY 3 WEEKS) (Esophageal, Gastric, and Lung Cancer)
PACLITAXEL + CISPLATIN
PEMBROLIZUMAB + CARBOPLATIN + DOCETAXEL
PEMBROLIZUMAB + CISPLATIN + DOCETAXEL
POLATUZUMAB +/- BENDAMUSTINE +/- RITUXIMAB
RAMUCIRUMAB + DOCETAXEL
RITUXIMAB + BENDAMUSTINE + CYTARABINE
RITUXIMAB + CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRIStINE + PREDNISONE (R-CHOP)
RITUXIMAB + CYCLOPHOSPHAMIDE + LIPOSOMAL DOXORUBICIN + VINCRIStINE + PREDNISONE REGIMEN (R-CDOP)
RITUXIMAB + DOXORUBICIN + BLEOMYCIN + VINBLASTINE + DACARBAZINE (R-ABVD)
RITUXIMAB + FLUDARABINE + CYCLOPHOSPHAMIDE (FCR)
RITUXIMAB + GEMCITABINE + DEXAMETHASONE + CARBOPLATIN (R-GDP)
RITUXIMAB + GEMCITABINE + DEXAMETHASONE + CISPLATIN (R-GDP)
SACITUZUMAB GOVITECAN-HZIY
TAFASITAMAB-CXIX + LENALIDOMIDE

TRABECTEDIN
VINORELBINE + TRASTUZUMAB

ATTACHMENT C: HIGH RISK REGIMENS (GREATER THAN 20% FN RISK)

Regimen Name
(NORDIC) RITUXIMAB+CYCLOPHOSPHAMIDE+VINCRIStINE+DOXORUBICIN+PREDNISOLONE/RITUXIMAB+CYTARABINE
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)-RYWN
ATRA + ARSENIC TRIOXIDE + GEMTUZUMAB
AVAPRITINIB
AXICABTAGENE CILOLEUCEL
BEVACIZUMAB + TOPOTECAN
BLEOMYCIN + ETOPOSIDE + DOXORUBICIN + CYCLOPHOSPHAMIDE + VINCRIStINE + PROCARBAZINE + PREDNISONE
BLINATUMOMAB
BLINATUMOMAB +/- BOSUTINIB or DASATINIB or NILOTINIB or PONATINIB or IMATINIB
BORTEZOMIB + DEXAMETHASONE + THALIDOMIDE + CISPLATIN + DOXORUBICIN + CYCLOPHOSPHAMIDE + ETOPOSIDE
BORTEZOMIB + DEXAMETHASONE + THALIDOMIDE + CISPLATIN + DOXORUBICIN + CYTOXAN + ETOPOSIDE (VTD-PACE)
CALGB 10403 CONSOLIDATION (CYCLOPHOSPHAMIDE + CYTARABINE + VINCRIStINE + PEGASPARGASE + MERCAPTOPURINE + METHOTREXATE)
CALGB 10403 CONTINUATION MAINTENANCE (VINCRIStINE + PEGASPARGASE + MERCAPTOPURINE + METHOTREXATE)
CALGB 10403 DELAYED INTENSIFICATION (METHOTREXATE + DEXAMETHASONE + DOXORUBICIN + PEGASPARGASE + CYCLOPHOSPHAMIDE + THIUGUANINE + CYTARABINE)
CALGB 10403 INDUCTION (DAUNORUBICIN + VINCRIStINE + PREDNISONE + PEGASPARGASE)
CALGB 10403 INTERIM MAINTENANCE (VINCRIStINE + PEGASPARGASE + MERCAPTOPURINE + METHOTREXATE)
CALGB 10403 REMISSION INDUCTION (DAUNORUBICIN + VINCRIStINE + PREDNISONE + PEGASPARGASE)
CALGB 8811 EARLY INTENSIFICATION (CYCLOPHOSPHAMIDE + MERCAPTOPURINE + CYTARABINE + METHOTREXATE + VINCRIStINE + PEGASPARGASE)
CALGB 8811 INDUCTION (DAUNORUBICIN + VINCRIStINE + PREDNISONE + PEGASPARGASE + CYCLOPHOSPHAMIDE)
CALGB 8811 LATE INTENSIFICATION (DOXORUBICIN + VINCRIStINE + DEXAMETHASONE + CYCLOPHOSPHAMIDE + THIUGUANINE + CYTARABINE)
CARBOPLATIN + DOCETAXEL + CETUXIMAB

CARMUSTINE + CYTARABINE + ETOPOSIDE + MELPHALAN (MINI-BEAM)
CISPLATIN + CYTARABINE + DEXAMETHASONE (DHAP)
CISPLATIN + CYTARABINE + DEXAMETHASONE (DHAP) + BRENTUXIMAB
CISPLATIN + DOCETAXEL + CETUXIMAB
CYCLOPHOSPHAMIDE + CISPLATIN + ETOPOSIDE + STEROID (DCEP)
DEXAMETHASONE + CYTARABINE + OXALIPLATIN (DHAX)
DOCETAXEL + CARBOPLATIN + TRASTUZUMAB (TCH)
CISPLATIN + ETOPOSIDE (Carcinoid, Head and Neck)
DOCETAXEL + CARBOPLATIN + TRASTUZUMAB + PERTUZUMAB (TCHP)
DOCETAXEL + CISPLATIN (Gastric Cancer)
DOCETAXEL + CISPLATIN + FLUOROURACIL (DCF- Head and Neck Cancer)
DOCETAXEL + CYCLOPHOSPHAMIDE (TC)
DOCETAXEL + CYCLOPHOSPHAMIDE + TRASTUZUMAB
DOCETAXEL + DOXORUBICIN + CYCLOPHOSPHAMIDE (TAC)
DOSE DENSE METHOTREXATE + VINBLASTINE + DOXORUBICIN + CISPLATIN (DD-MVAC)
DOSE-DENSE DOXORUBICIN + CYCLOPHOSPHAMIDE (AC)
DOSE-DENSE DOXORUBICIN + CYCLOPHOSPHAMIDE (AC) FOLLOWED BY Docetaxel
DOSE-DENSE DOXORUBICIN + CYCLOPHOSPHAMIDE (AC) FOLLOWED BY PACLITAXEL
DOSE-DENSE DOXORUBICIN + CYCLOPHOSPHAMIDE (AC) FOLLOWED BY PERTUZUMAB + TRASTUZUMAB + PACLITAXEL
DOXORUBICIN + DACARBAZINE (AD)
DOXORUBICIN
DOXORUBICIN + GEMCITABINE + IFOSFAMIDE + MESNA
DOXORUBICIN + IFOSFAMIDE + MESNA (AIM)
DOXORUBICIN + VINBLASTINE + DACARBAZINE (AVD) + BRENTUXIMAB
ETOPOSIDE + CYTARABINE
ETOPOSIDE + CYTARABINE + DAUNORUBICIN
ETOPOSIDE + CYTARABINE + IDARUBICIN
ETOPOSIDE + IFOSFAMIDE + MESNA + CISPLATIN
ETOPOSIDE + IFOSFAMIDE + MITOXANTRONE
ETOPOSIDE + METHYLPREDNISOLONE + CISPLATIN + CYTARABINE (ESHAP)
ETOPOSIDE + METHYLPREDNISOLONE + CYTARABINE + CISPLATIN (ESHAP)

ETOPOSIDE + METHYLPREDNISOLONE + CYTARABINE + CISPLATIN (ESHAP) + BRENTUXIMAB
ETOPOSIDE + PREDNISONE + VINCRISTINE + CYCLOPHOSPHAMIDE + DOXORUBICIN (DOSE ADJUSTED EPOCH)
ETOPOSIDE + PREDNISONE + VINCRISTINE + CYCLOPHOSPHAMIDE + DOXORUBICIN (EPOCH)
FOLFOXIRI
FOLFOXIRI + BEVACIZUMAB
FOLFOXIRI + CETUXIMAB
FOLFOXIRI + PANITUMUMAB
GEMCITABINE + CARBOPLATIN + DEXAMETHASONE (GCD)
GEMCITABINE + DOCETAXEL
GEMCITABINE + VINOURELBINE + LIPOSOMAL DOXORUBICIN (GVD)+ PEMBROLIZUMAB
HIGH DOSE METHOTREXATE + CYTARABINE
HYPER-CVAD ± RITUXIMAB (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE): CYCLE A COURSE
HYPER-CVAD ± RITUXIMAB (HIGH DOSE METHOTREXATE/CYTARABINE): CYCLE B COURSE
HYPER-CVAD ± RITUXIMAB + BOSUTINIB (HIGH DOSE METHOTREXATE/CYTARABINE): CYCLE B COURSE
HYPER-CVAD ± RITUXIMAB + BOSUTINIB (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE): CYCLE A COURSE
HYPER-CVAD ± RITUXIMAB + DASATINIB (ALTERNATE WITH METHOTREXATE/CYTARABINE): CYCLE B COURSE
HYPER-CVAD ± RITUXIMAB + DASATINIB (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE): CYCLE A COURSE
HYPER-CVAD ± RITUXIMAB + IMATINIB (ALTERNATE WITH METHOTREXATE/CYTARABINE): CYCLE B COURSE
HYPER-CVAD ± RITUXIMAB + IMATINIB (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE): CYCLE A COURSE
HYPER-CVAD ± RITUXIMAB + NILOTINIB (ALTERNATE WITH METHOTREXATE/CYTARABINE): CYCLE B COURSE
HYPER-CVAD ± RITUXIMAB + NILOTINIB (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE): CYCLE A COURSE
HYPER-CVAD ± RITUXIMAB + PONATINIB (ALTERNATE WITH METHOTREXATE/CYTARABINE): CYCLE B COURSE
HYPER-CVAD ± RITUXIMAB + PONATINIB (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE): CYCLE A COURSE
IFOSFAMIDE + MESNA + CARBOPLATIN + ETOPOSIDE (ICE)

IFOSFAMIDE + MESNA + CARBOPLATIN + ETOPOSIDE (ICE) + BRENTUXIMAB
IFOSFAMIDE + MESNA + CISPLATIN
IFOSFAMIDE + MESNA + EPIRUBICIN
IFOSFAMIDE + MESNA + ETOPOSIDE + CARBOPLATIN (ICE)
IFOSFAMIDE + MESNA + GEMCITABINE + VINOELBINE (IGEV)
IFOSFAMIDE + MESNA + GEMCITABINE + VINOELBINE + PREDNISONE (IGEV) +/- BRENTUXIMAB
INOTUZUMAB OZOGAMICIN
INOTUZUMAB OZOGAMICIN + MINI-HYPER-CVD (CYCLOPHOSPHAMIDE + VINCRISTINE + METHOTREXATE + DEXAMETHASONE + CYTARABINE + MESNA)
INOTUZUMAB OZOGAMICIN +/- BOSUTINIB or DASATINIB or NILOTINIB or PONATINIB or IMATINIB
MESNA + DOXORUBICIN + IFOSFAMIDE + DACARBAZINE (MAID)
MESNA + IFOSFAMIDE + MITOXANTRONE + ETOPOSIDE (MINE)
METHOTREXATE + VINBLASTINE + DOXORUBICIN + CISPLATIN (MVAC)
NILOTINIB
OXALIPLATIN + IRINOTECAN + LEUCOVORIN + FLUOROURACIL (FOLFIRINOX)
OXALIPLATIN + IRINOTECAN + LEUCOVORIN + FLUOROURACIL (MODIFIED FOLFIRINOX) +/- BEVACIZUMAB
PACLITAXEL + IFOSFAMIDE + MESNA
PACLITAXEL + IFOSFAMIDE + MESNA (FOLLOWED BY CARBOPLATIN AND ETOPOSIDE AS HIGH-DOSE CHEMO)
PACLITAXEL+ IFOSFAMIDE + MESNA + CISPLATIN
RITUXIMAB + CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (R-CHOP)/RITUXIMAB + DHAP
RITUXIMAB + CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE (MODIFIED HYPERCVAD)
RITUXIMAB + CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE (R-HYPER-CVAD)
RITUXIMAB + CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE/METHOTREXATE + CYTARABINE
RITUXIMAB + CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + METHOTREXATE (R-CODOX-M)
RITUXIMAB + DEXAMETHASONE + CYTARABINE + OXALIPLATIN (R-DHAX)
RITUXIMAB + ETOPOSIDE + METHYLPREDNISOLONE + CISPLATIN + CYTARABINE (R-ESHAP)
RITUXIMAB + ETOPOSIDE + PREDNISONE + VINCRISTINE + CYCLOPHOSPHAMIDE + DOXORUBICIN (DA-R-EPOCH)



RITUXIMAB + ETOPOSIDE + PREDNISONE + VINCRISTINE + CYCLOPHOSPHAMIDE + DOXORUBICIN (R-EPOCH)
RITUXIMAB + GEMCITABINE + CYCLOPHOSPHAMIDE + VINCRISTINE + PREDNISONE (R-GCVP)
RITUXIMAB + GEMCITABINE + DEXAMETHASONE + CISPLATIN (R-GDP)
RITUXIMAB + IFOSFAMIDE + ETOPOSIDE + CYTARABINE (R-IVAC)
RITUXIMAB + IFOSFAMIDE + MESNA + CARBOPLATIN + ETOPOSIDE (R-ICE)
RITUXIMAB + IFOSFAMIDE + MESNA + GEMCITABINE + VINORELBINE (R-IGEV)
RITUXIMAB + MESNA + IFOSFAMIDE + MITOXANTRONE + ETOPOSIDE (R-MINE)
STEROID + THALIDOMIDE + CISPLATIN + DOXORUBICIN + CYCLOPHOSPHAMIDE + ETOPOSIDE (DT-PACE)
TISAGENLECLEUCEL (Acute Lymphoblastic Leukemia, Follicular Non-Hodgkin's Lymphoma)
TOPOTECAN (IV) DAYS 1-5 EVERY 3 WEEKS DOSING ONLY
TOPOTECAN (ORAL) DAYS 1-5 EVERY 3 WEEKS DOSING ONLY
TOPOTECAN + SORAFENIB
TRETINOIN + ARSENIC TRIOXIDE + GEMTUZUMAB
VENETOCLAX + MINI-HYPER-CVD (CYCLOPHOSPHAMIDE + VINCRISTINE + METHOTREXATE + DEXAMETHASONE + CYTARABINE + MESNA)
VINCRISTINE + CYCLOPHOSPHAMIDE + PREDNISONE + PROCARBAZINE + ETOPOSIDE + DOXORUBICIN + BLEOMYCIN
VINBLASTINE + IFOSFAMIDE + MESNA + CISPLATIN

ATTACHMENT D: MGF INDICATIONS FOR FEBRILE NEUTROPENIA PRIMARY AND SECONDARY PROPHYLAXIS

Primary Prophylaxis of FN	Secondary Prophylaxis of FN
<u>Definition</u> Use of a G-CSF to prevent febrile neutropenia* in a patient receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.	<u>Definition</u> - Per NCCN Guidelines for Management of Neutropenia (growthfactors.pdf (nccn.org)): - Secondary prophylaxis with G-CSFs is recommended after a febrile neutropenic <u>or</u> dose-limiting neutropenic event* during prior chemotherapy cycle. - Per ASCO Guidelines (Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update (ascopubs.org)): - Secondary prophylaxis with a CSF is recommended for patients who experienced a neutropenic complication from a prior cycle of chemotherapy (for which primary prophylaxis was not received), in which a reduced dose or treatment delay may compromise disease-free or overall survival or treatment outcome. In many clinical situations, dose reduction or delay may be a reasonable alternative.
<u>Additional Definitions</u> Febrile Neutropenia: defined as single temp $\geq 38^{\circ}\text{C}$ and <500 neutrophils/μL (ANC 0.5) or $<1,000$ neutrophils/μL (ANC 1.0) and a predicted decline to <500 over the next 48 hours. Dose-Limiting Neutropenic Event: - Per NCCN: <i>could be a nadir count or day of treatment count that could otherwise impact planned dose of chemotherapy</i> - Per AACR: <i>criteria for defining dose-limiting criteria (hematology)</i>: - Grade 3 neutropenia for >7 consecutive days - Grade 3 thrombocytopenia for >7 consecutive days - Grade 4 thrombocytopenia Febrile neutropenia (ANC, including bands, $<1.0 \times 10^9/\text{L}$, fever $\geq 38.5^{\circ}\text{C}$)	